Spirocyclic degronimers for target protein degradation
申请人:C4 Therapeutics, Inc.
公开号:US10660968B2
公开(公告)日:2020-05-26
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.